Rituximab Induction Results in High Overall Survival in Low-Tumor-Burden Follicular Lymphoma

Share this content:
(ChemotherapyAdvisor) – Following a single 4-dose rituximab induction in first line low-tumor-burden follicular lymphoma, a significant proportion of patients remained progression-free 7 years later, a study reported in the Annals of Oncology online July 10.

“The 7-year overall survival is very high in this selected population of patients,” noted Prof. Philippe Colombat, of Bretonneau University Hospital, Tours, France, and colleagues. The study reported long-term clinical and molecular responses in 46 of 49 patients with low-tumor-burden follicular lymphoma who had received rituximab 375 mg/m2 weekly as induction monotherapy.

Best clinical response was found to be 80%; 24 patients (52%) had complete or unconfirmed complete response, 13 (28%) had partial response, and 9 (20%) had stable or progressive disease. Following treatment, 15 of 31 patients (48%) who had a positive bcl2-JH rearrangement became negative.

At 83.9-month (95% CI 6.4–92.8) follow-up, median progression-free survival was 23.5 months and overall survival, 91.7%, the investigators reported. Of the 5 deaths, one each was attributed to disease progression, myelodysplasia, and diffuse large B-cell lymphoma and two to solid tumors. A total of 7 patients (15%) remain progression-free, including 5 who are bcl2 informative.

“No unexpected long-term adverse event has been observed,” they concluded.

Abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs